1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Europe Nuclear Medicine Market - Trends and Forecasts(2016 - 2021)

Europe Nuclear Medicine Market - Trends and Forecasts(2016 - 2021)

  • August 2016
  • -
  • Mordor Intelligence LLP
  • -
  • 101 pages

The European nuclear medicine market is expected to reach USD 4,660 million by the end of 2019, growing at a CAGR of around 10% from 2014 to 2019.



Nuclear medicine utilizes radioisotopes for application in diagnosis and treatment of diseases. The drugs containing radionuclides are said to be radiopharmaceuticals. Their uses in radiological imaging include Magnetic Resonance Imaging (MRI), Computerized tomography (CT), Positron Emission Tomography (PET) and Single Proton Emission Tomography (SPECT).



Europe Nuclear Medicine Market-Market Dynamics



The use of nuclear medicine for diagnostic purposes is gaining importance in Europe rapidly. There has been increased use of SPECT, PET, CT and MRI for diagnosis of cardiac diseases, brain diseases, cancer and many others. Nuclear medicine is being used for therapeutic purposes for treatment of Alzheimer’s disease, coronary heart diseases, bone metastasis, different medical conditions affecting the thyroid gland, scar -tissue removal and many cancers. In Europe, treatment for thyrotoxicosis through nuclear medicine has a large share in nuclear medicine therapeutics market. Advancements in diagnostic imaging are bringing in more use of nuclear medicine.





Drivers



The key driving factor for the market in Europe is the umbrella organization for nuclear medicine, the European Association for Nuclear Medicine (EANM) in Europe, which stands ready for political follow-up and professional input to guarantee patient care and safety throughout Europe. Other driving factors include:





Increasing incidence of cancer, thyroidal diseases, endocrinal diseases, and cardiac ailments

Rise in applications of SPECT and PET with advancement of technology

Growing awareness amongst physicians

Public awareness for better healthcare







Restraints



Some of the factors restraining the market growth are:





Short half-life of radiopharmaceuticals

High capital investment required for development

Stringent regulatory guidelines





Opportunities



The market offers ample opportunities to the players in the form of:





Increasing imaging technologies

Potential radioisotopes in the pipeline

Increasing neurological applications

Increasing cyclotron-based production





The European nuclear medicine market has been segmented based on type and application. The segmentation based on type of product has been further divided based on diagnostic market and therapeutic market, wherein, the diagnostics market has been further subdivided into SPECT radioisotopes that include Technetium-993, Thallium-201, Iodine-123, Gallium and PET radioisotopes that include Rubidium-82, Flourine-18, and the therapeutics category has been segmented into Alpha emitters (Radium-223), Beta Emitters(includes Iodine-131, Samarium-153, Lutetium-177, Yttrium-90) and Brachytherapy (includes iodine-125, Cesium-131, Palladium-103, & Iridium-192). The segmentation based on application has been similarly subdivided based on diagnostic and therapeutic application. The diagnostic application includes the application of SPECT and PET in Cardiology, Neurology, Oncology and others. The therapeutic applications include application in Oncology, Thyroid, Endocrinology and various other therapeutic areas.



On the basis of geography, the market has been segmented into the United Kingdom, Germany, France, Scandinavia, Italy, Spain, and the Benelux countries. Upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. France, UK, and Germany lead when it comes to the use of nuclear medicine.



Currently, diagnostics segment holds the largest share in nuclear medicine market, in which SPECT has the largest share. In the segmentation based on type, the Beta Emitters hold the largest share.





Some of the key players in the market are:





Cardinal Health, Inc.

GE Healthcare

IBA Group

Lantheus Medical Imaging

Nordion, Inc.

NTP Radioisotopes

Siemens Healthcare

Triad Isotope







What the Report Offers





Market definition for the European nuclear medicine market along with identification of key drivers and restraints for the market.

Market analysis for the European nuclear medicine market, with region-specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.

Identification and analysis of the macro and micro factors that affect the European nuclear medicine market on a regional scale.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.



Table Of Contents

Europe Nuclear Medicine Market - Trends and Forecasts(2016 - 2021)
1. Introduction



1.1 Study deliverables



1.2 Market Definition



1.3 Sizing Units



1.4 Base Currency



1.5 Review and Forecast period years



1.6 General Study Assumptions



2. Research Methodology



2.1 Introduction



2.2 Analysis Methodology



2.3 Econometric Forecast Model



2.4 Research Assumptions



3. Executive Summary



4. Key Inferences



5. Market Overview and Industry trends



5.1 Current Market Scenario



5.2 Nuclear Medicine Applications



5.3 Technology Overview



5.4 New Developments



5.5 Industry Value chain analysis



5.6 product Lifecycle analysis



5.7 Product Benchmarking



5.8 Investment Analysis



5.9 Porter's Five Forces



5.9.1 Bargaining Power of Suppliers



5.9.2 Bargaining Power of Consumers



5.9.3 Threat to new entrants



5.9.4 Threat to substitute products and services



5.9.5 Competitive Rivalry within the industry



6. Drivers, Restraints, Opportunities, and challenges Analysis



6.1 Market Drivers



6.1.1 Increasing incidents of Cancer and Cardiac Ailments



6.1.2 Increasing SPECT and PET applications



6.1.3 Growing awareness amongst Physicians and Public usage of Advanced healthcare facilities



6.2 Market Restraints



6.2.1 Short half-life of Radiopharmaceuticals



6.2.2 High Capital Investment



6.2.3 Regulatory Guidelines



6.3 Opportunities



6.3.1 Increasing Imaging Technologies



6.3.2 Potential Radioisotopes in Pipeline



6.3.3 Increasing Neurological Applications



6.3.4 Cyclotron Based Production



6.4 Threats



6.4.1 Shutdown of Nuclear Reactors



7. Europe Nuclear Medicine Market Segmentation



7.1 Nuclear Medicine Market, by Type of Product



7.1.1 Diagnostic Market



7.1.1.1 SPECT Radioisotopes



7.1.1.1.1 Technetium-99m (TC-99m)



7.1.1.1.2 Thallium-201 (Tl-201)



7.1.1.1.3 Iodine (I-123)



7.1.1.1.4 Gallium-67 (Ga-67)



7.1.1.1.5 Others



7.1.1.2 PET Radioisotopes



7.1.1.2.1 Rubidium-82



7.1.1.2.2 Fluorine-18



7.1.1.2.3 Others



7.1.2 Therapeutics Market



7.1.2.1 Alpha Emitters



7.1.2.1.1 Radium-223 (Ra-223)



7.1.2.2 Beta Emitters



7.1.2.2.1 Iodine-131 (I-131)



7.1.2.2.2 Samarium-153 (Sm-153)



7.1.2.2.3 Rhenium-186 (Re-186)



7.1.2.2.4 Lutetium-177 (Lu-177)



7.1.2.2.5 Yttrium-90 (Y-90)



7.1.2.2.6 Others



7.1.2.3 Brachtherapy



7.1.2.3.1 Iodine-125 (I-125)



7.1.2.3.2 Cesium-131 (Cs-131)



7.1.2.3.3 Palladium-103



7.1.2.3.4 Iridium-192



7.1.2.3.5 Others



7.2 Nuclear Medicine Market, by Application



7.2.1 Introduction



7.2.2 Diagnostics



7.2.2.1 PET



7.2.2.1.1 Cardiology



7.2.2.1.2 Neurology



7.2.2.1.3 Oncology



7.2.2.1.4 Others



7.2.2.2 SPECT



7.2.2.2.1 Cardiology



7.2.2.2.2 Neurology



7.2.2.2.3 Oncology



7.2.2.2.4 Others



7.2.3 Therapeutics



7.2.3.1 Oncology



7.2.3.2 Thyroid



7.2.3.3 Endocrinology



7.2.3.4 Others



8. Market segmentation by Geography - Europe Share and forecast



8.1 Europe



8.1.1 Introduction



8.1.2 United Kingdom



8.1.3 Germany



8.1.4 France



8.1.5 Spain



8.1.6 Italy



8.1.7 Scandinavia



8.1.8 Others



9. Competitive Landscape



9.1 Merger and acquisition analysis



9.2 New Product Launches



9.3 Agreements, Collaborations, and Partnerships



10. Key Vendor Analysis



10.1 Mallinckrodt



10.2 Lantheus Medical Imaging



10.3 IBA Group



10.4 Triad Isotope



10.5 Siemens Healthcare



10.6 NTP Radioisotopes



10.7 Cardinal Health, Inc.



10.8 GE Healthcare



10.9 Nordion, Inc.



10.10 Fujifilm Holding Corporation



11. Analyst outlook for Investment opportunities



12. Future Outlook of the market

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The nuclear medicine/radiopharmaceuticals market is projected to reach USD 7.27 billion by 2021 from USD 4.67 billion in 2016, growing at a CAGR of 9.3% in the next five years (2016 to 2021). Over the ...

Global Nuclear Medicine Market

Global Nuclear Medicine Market

  • $ 4250
  • Industry report
  • October 2016
  • by Mordor Intelligence LLP

The global nuclear medicines market is expected to reach USD 17,600 million by the end of 2020, growing at a CAGR of around 12.29% from 2015 to 2020. Nuclear medicine utilizes the radioisotope for application ...

Global and Chinese European Nuclear Medicine / Radiopharmaceuticals Industry, 2016 Market Research Report

Global and Chinese European Nuclear Medicine / Radiopharmaceuticals Industry, 2016 Market Research Report

  • $ 3000
  • Industry report
  • November 2016
  • by Prof Research

The ’Global and Chinese European Nuclear Medicine / Radiopharmaceuticals Industry, 2011-2021 Market Research Report’ is a professional and in-depth study on the current state of the global European ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.